Huaren Pharmaceutical's ANDA205357 for Valsartan Receives AP Status
Huaren Pharmaceutical Co Ltd's ANDA205357 for Valsartan has received an Abbreviated Approval (AP) status from the FDA.
Asset / Drug
Drug and asset intelligence for Valsartan with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has approved ANDA204687, a generic formulation of Valsartan and Hydrochlorothiazide, submitted by Sciegen Pharmaceuticals.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.